The changing treatment landscape in idiopathic pulmonary fibrosis

European Respiratory Review

Volumn 24, Issue 135, 2015, Pages 65-68

  Costabel, Ulrich ^a  

^a RUHRLANDKLINIK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

DISEASE SEVERITY; DRUG APPROVAL; DRUG TOLERABILITY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MEDICATION THERAPY MANAGEMENT; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SURVIVAL; TREATMENT PLANNING; EUROPE; IDIOPATHIC PULMONARY FIBROSIS; MORTALITY; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EUROPE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRACTICE GUIDELINES AS TOPIC; PYRIDONES; UNITED STATES;

EID: 84923920911     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00011414     Document Type: Review

References (36)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
2. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431–440.
3. Cordier JF, Cottin V. Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. Eur Respir J 2013; 42: 916–923.
4. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980–985.
5. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338–342.
6. Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009; 103: 1122–1129.
7. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011; 66: 462–467.
8. Thomeer MJ, Costabe LU, Rizzato G, et al. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J 2001; 18: Suppl. 32, 114s–118s.
9. von Plessen C, Grinde O, Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med 2003; 97: 428–435.
10. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636–643.
11. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 285–292.
12. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008; 3: 8.
13. Meyer C, Nathan SD. Idiopathic Pulmonary Fibrosis: a Comprehensive Clinical Guide. Totowa, NJ, Humana Press, 2013.
14. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
15. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 2011; 377: 1760–1769.
16. National Institutes of Health. Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful. Press Release October 21, 2011. www.nih.gov/news/health/oct2011/nhlbi-21.htm
17. Noth I, Anstrom KJ, Calvert SB. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Care Med 2012; 186: 88–95.
18. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
19. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646–664.
20. European Medicines Agency. CHMP assessment report EMA/CHMP/115147/2011 www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002154/WC500103073.pdf Date last updated: December 16, 2010. Date last accessed: November 19, 2014.
21. Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2093–2101.
22. Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 198–205.
23. Chaudhuri N, Duck A, Frank R, et al. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med 2014; 108: 224–226.
24. Bonella F, Wessendorf TE, Costabel U. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis]. Dtsch Med Wochenschr 2013; 138: 518–523.
25. Oltmanns U, Kahn N, Wenz H, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral centre for interstitial lung diseases. Eur Respir J 2013; 42: Suppl. 57, p2335.
26. Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013; 107: 1431–1437.
27. Arai T, Inoue Y, Sasaki Y, et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig 2014; 52: 136–143.
28. Ravaglia C, Gurioli C, Romagnoli M, et al. Pirfenidone treatment in idiopathic pulmonary fibrosis: an Italian case series. Eur Respir J 2013; 42: Suppl. 57, p3370.
29. Nieto Barbero MA, Valenzuela C, Rivera Ortega P, et al. Pirfenidone in idiopathic pulmonary fibrosis (IPF): early Spanish experience with the European named patient program (NPP). Eur Respir J 2013; 42: Suppl. 57, p2361.
30. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 740–747.
31. Annex I. Summary of Product Characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002154/WC500103049.pdf Date last updated: October 2014. Date last accessed: November 19, 2014.
32. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adver Ther 2014; 31: 375–391.
33. U.S. Food and Drug Administration. FDA approves Esbriet to treat idiopathic pulmonary fibrosis. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm Date last updated: October 15, 2014. Date last accessed: November 19, 2014.
34. Maher TM. A clinical approach to diffuse parenchymal lung disease. Immunol Allergy Clin North Am 2012; 32: 453–472.
35. Putman RK, Rosas IO, Hunninghake GM. Genetics and early detection in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 189: 770–778.
36. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med 2014; 2: 933–942.